Zepbound: The Rising Rival to Ozempic

Zepbound, the new weight loss drug from Eli Lilly, has been approved by the FDA as a competitor to Ozempic. It mimics the GLP-1 hormone and the body's GIP hormone to regulate sugar levels and appetite. Trial participants saw an average weight loss of 18 percent. However, Zepbound has common side effects like nausea and diarrhea. The approval comes amid a national shortage of weight loss drugs, driving desperate patients to seek illegal or compounded versions. Zepbound's high price tag may still lead some patients to take dangerous routes to obtain the medication.